Navigation Links
Cleveland Clinic receives grant to study role of DNA damage in treatment-resistant prostate cancer
Date:12/18/2013

Wednesday, December 18, 2013: Cleveland Clinic, along with the National Cancer Institute, the University of Chicago and Thomas Jefferson University, are the recipients of a $600,000 Special Challenge Award from the Prostate Cancer Foundation (PCF) to investigate the role of abnormally high protein levels in prostate tumors.

The increased expression of approximately 25 proteins referred to as interferon-related DNA damage resistance signature (IRDS) correlates strongly with resistance to radiation and chemotherapy. African-American men with prostate cancer are much more likely to have the IRDS signature than Caucasian men, one potential reason for the observed differences in mortality from the disease.

"African-American men have a two-fold higher mortality rate from prostate cancer than European-Americans," said Eric Klein, M.D., Chairman, Glickman Urological & Kidney Institute at Cleveland Clinic, and principal investigator on the grant. "The goal of our research is to further investigate the biology behind the obvious aggressive behavior of prostate tumors in African-American men in the hopes of better understanding its biology and identifying new management and treatment options."

Cleveland Clinic is at the forefront of identifying and addressing health disparities through multidisciplinary clinical care, community outreach and education. In 2003, the Minority Men's Health Center, led by urologist Charles S. Modlin, M.D., MBA, was established in the Glickman Urological & Kidney Institute to address the vast number of medical conditions which disproportionately affect minority men. Approximately 750 patients visited the center this year, in addition to the more than 1,000 men who attend the annual Minority Men's Health Fair each April.

Prostate cancer tumors develop IRDS when exposed to interferons, potent antiviral proteins naturally produced by the body in response to a virus, bacteria or tumor cells. Inteferons were previously thought to prevent tumors from growing; however, research has shown their presence in certain tumors actually inhibits the effectiveness of traditional chemotherapy or radiation. Why this happens more frequently in African-American men is still unknown.

"We don't know whether the tumors themselves or tumor-associated immune cells are the primary sources of the interferon which enables the cancer cells to resist therapy or how such resistance is achieved," said George Stark, Ph.D., staff researcher in molecular genetics in Cleveland Clinic's Lerner Research Institute and principal investigator on the grant. "These questions are being actively investigated in our laboratories."

Part of the study will involve testing drugs conventionally used to treat other cancers to determine if they will block the growth response of prostate tumors when exposed to interferons, improving the tumor's response to chemotherapy or radiation and increasing survival rates. The grant provided by PCF, a philanthropic organization that seeks to fund and accelerate prostate cancer research globally will be also used to study a wide range of other clinical issues in IRDS-positive tumors.

"Overall, we hope our research will provide patients with IRDS-positive tumors a therapeutic approach that improves outcomes," said Dr. Klein.

Other Cleveland Clinic investigators involved in this research project include Andrew Stephenson, M.D. and Robert Silverman, Ph.D.


'/>"/>

Contact: Stephanie Jansky
JANSKYS@ccf.org
216-636-5869
Cleveland Clinic
Source:Eurekalert

Related medicine news :

1. FastFingerprints Expands in the Cleveland, Ohio Area
2. Clevelanders: Lighting up in a new way
3. NFL Punter Spencer Lanning of the Cleveland Browns Continues Fundraising Effort to Help Kicking For The Dream Fight Ovarian Cancer
4. Medical Experts Gather at Cleveland Clinic Lou Ruvo Center for Brain Health for Annual Silverado Medical Director Conference
5. Cleveland Treatment Center Launches Video Detailing Its Services for Drug, Alcohol Recovery
6. Explorys Selected as One of the Top 25 “Coolest Tech” Companies in Cleveland by Inside Business and Expedient
7. StartUp Health Showcases Digital Health Companies during Cleveland Clinic Medical Innovation Summit
8. Cleveland ENT, Dr. Bert Brown MD, Launches New Website
9. American Brain Tumor Association and Cleveland Clinic Conference Offers Continuing Education to Health Care Professionals
10. Cleveland Clinics preventive breast cancer vaccine development takes step forward
11. Cleveland Clinic research: Most statin-intolerant patients can eventually tolerate statins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Ill. (PRWEB) , ... October ... ... Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer ... healthcare professionals on guideline updates for the primary prevention of cardiovascular diseases ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Mohebi Hair Restoration, has recently contributed a medical article to the newly revamped ... cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
Breaking Medicine Technology: